SPOTLIGHT: Merck scraps AIDS vaccine

Over the weekend Merck announced that it was scrapping development of a promising AIDS vaccine after researchers concluded that it had failed a large international study. This was considered a major setback in the effort to develop an AIDS vaccine. In the trial, 24 volunteers receiving the vaccine contracted AIDS compared to 21 in the control group. Release

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.